SEC Form 4 · accession 0001209191-17-038881
ANTARES PHARMA, INC. · ATRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marvin Samson
Director
Period of report
Jun 7, 2017
Accepted (ET)
Jun 9, 2017 · 4:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $2.66 | Jun 7, 2017 | A | 80,318 | A | — | Jun 7, 2027 | Common Stock | 80,318 | 80,318 | D |
Explanation of responses
- F1Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan.
- F2The options vest in equal quarterly installments over one year from grant date.